IGI Logo
Toggle Navigation
News
Hindi
Hindi News
Top News
Screeners
Stocks
Stocks Screener
Stock
News
Stock Market Home Page
Stock News
Industry News
Economy News
Stock on the move
Expert Views
Research Reports
Company Result
Comp Info And Fundamentals
Company Profile
Equity
Financial Ratios
Results
Balance Sheet
Profit And Loss
Cash Flow
Share Holding
Derivatives (F&O)
Get Quotes
Market Watch
Top Gainers
Top Losers
Top Traded Quantity
Top Traded Value
Most Active Puts
Derivatives (F&O)
Most Active Calls
Put Call Ratio
Highest In Premium
Daily Settlement Price
FII and DII Statistics
Open Interest: Highest In OI
Open Interest: Lowest In OI
Derivatives (F&O)
Open Interest: Increase in OI Increase in Price
Open Interest: Decline in OI Decrease in Price
Derivative Watch
Derivatives Dashboard
Historical Data
List of Underlyings & Underlying Info
Derivative Watch
Derivatives Dashboard
Market Reports
Top Gainers
Top Losers
Monthly High/Low
52 Week High
52 Week Low
Market Cap Gainers
Market Cap Losers
PE Ratio
>More Market Reports
IPO
News
IPO News
IPO Issue Reports
Commodity
Commodity Market
Commodity Home Page
Commodity News
Commodity Reports
Market Details
Get Quotes
Top Gainers
Top Losers
Top Volume
Top Value
Top Gainers Spot Market
Top Losers Spot Market
High & Low
Commodity Indices
Technical Analysis
Advance Declines
High & Low
Highest In OI
Lowest OI
Increase In Open Interest(%)
Descrease In Open Interest(%)
Currency
News
Currency News
Economy News
Currency Reports
Mutual Fund
News
Mutual Fund Home Page
Mutual Fund News
Mutual Fund Details
Mutual Fund Home Page
Compare Scheme
Scheme Profile
Mutual fund Investment
Mutual Fund Share Holding
Mutual Fund Statistics
Mutual fund Gainers
Mutual fund Losers
Biggest Schemes
Best Performers
Latest Dividend Details
Tools
Multi Scheme Comparison Tool
Dividend Details
Performance Map
Mutual fund Investment
Mutual fund Share Holding
Mutual Fund Search Category Rankings
Widgets
Stock Widgets
Watchlist
Heatmap
Mutual Fund Widgets
Watchlist
Calculators
EMI Calculator
SIP Calculator
SWP Calculator
GST Calculator
FD Calculator
RD Calculator
Wealth
World
Tips
Intraday Tips
Market Outlook
Stock Tips
Commodity Tips
Currency Tips
Reports
Short Term Investment Opportunities
Long Term Investment Opportunities
Sector Analysis
Commodity Reports
Currency Reports
Mutual Fund Analysis
Podcast
Videos
Videos Category
Business Videos
Budget Videos
News And Politics
Entertainment Videos
Sports Videos
Lifestyle And Fashion Videos
Global News Videos
Calculators
EMI Calculator
SIP Calculator
SWP Calculator
GST Calculator
FD Calculator
RD Calculator
More
Budget 2024
Astrology
Women
Politics
Entertainment
Car&Bike
Gadgets
Lifestyle
Sports
Health
Fashion
Diwali Reports
Diwali Expert Reports
News
Astrology
Beyond Market Car
Beyond Market Entertainment
Beyond Market Fashion
Beyond Market Gadgets
Beyond Market Health
Beyond Market India
Beyond Market Life Style
Beyond Market Sports
Broking Firm Views
Broking Firm Views - Long Term Report
Broking Firm Views - Sector Report
Broking Firm Views - Short Term Report
Budget 2024 Sector Reports
Budget Bites
Budget Economic Servey
Budget Expert Views
Budget Industry
Budget News
Budget Wishlist
Commodities
Commodities Reports
Commodity Top News
Company News
Company Result
Currency News
Currency Report
Currency Top News
Diwali Expert Views
Diwali Market Outlook
Diwali Report
Diwali Technical Report
Economy News
Expert View Institution
Expert Views
Industry News
IPO Analysis
IPO More News
IPO Reports
IPO Top News
Market Outlook
Mutual Fund Analysis
Mutual Fund Expert Views
Mutual Fund More News
Mutual Fund Top News
Podcast - Market Ki Awaaz
Special Event Expert Views
Special Event Reports
Startup
Startup Expections
Startup Speak
Stock Market
Stock On The Move
Top News
Top Stories
Videos
Videos Business
Videos Entertainment
Videos Global News
Videos Lifestyle And Fashion
Videos News And Politics
Videos Sports
Wealth
Women
World Market More News
World Top News
Search
Revenue surged, Margins Improved Zydus Lifesciences Ltd. is one of India’s leading vertically integrated pharmaceutical companies, with presence across the value chain, from manufacturing of finished dosage forms to active pharmaceutical ingredients, animal healthcare products, and wellness products. ? In Q1FY24, the company’s consolidated revenue rose a significant 29.6% YoY to Rs. 5,140cr, primarily propelled by the US formulations business, which surged 57.4% YoY. ? EBITDA a...
Buy Zydus Lifesciences Ltd For Target Rs.750 - Geojit Financial Services Ltd
Zydus Lifesciences is currently trading at Rs. 652.40, up by 7.75 points or 1.20% from its previous closing of Rs. 644.65 on the BSE. The scrip opened at Rs. 655.00 and has touched a high and low of Rs. 659.00 and Rs. 647.20 respectively. So far 18824 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 668.50 on 10-Aug-2023 and a 52 week low of Rs. 350.30 on 26-Sep-2022. Last one week high and low of the scrip stood...
Zydus Lifesciences rises on getting USFDA`s final nod for Doxepin Tablets
US quarterly revenue at historical high Work in progress to enhance product pipeline * Zydus Life Sciences (ZYDUSLIF) beat our earnings estimates in 1QFY24, aided by strong traction in exports to the US and EU, and healthy YoY growth in the domestic formulation (DF) and API segments. * We raise our FY24/FY25 earnings estimates by 8%/4% to factor in niche product launches in the US generics segment, seasonal impact on consumer healthcare brands, and DF segment growth in line with mark...
Netrual Zydus LifeSciences Ltd For Target Rs.610 - Motilal Oswal
Zydus Lifesciences shines on getting nod to manufacture, market 50mg Indomethacin suppositories Aug-03-2023 11:50 Hrs IST Zydus Lifesciences is currently trading at Rs. 648.25, up by 20.15 points or 3.21% from its previous closing of Rs. 628.10 on the BSE. The scrip opened at Rs. 620.05 and has touched a high and low of Rs. 651.30 and Rs. 620.05 respectively. So far 20489 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched...
Zydus Lifesciences shines on getting nod to manufacture, market 50mg Indomethacin suppositories
Zydus Lifesciences is currently trading at Rs. 645.95, up by 23.50 points or 3.78% from its previous closing of Rs. 622.45 on the BSE. The scrip opened at Rs. 625.95 and has touched a high and low of Rs. 656.50 and Rs. 623.40 respectively. So far 84120 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 656.50 on 27-Jul-2023 and a 52 week low of Rs. 340.60 on 27-Jul-2022. Last one week high and low of the scrip stoo...
Zydus Lifesciences jumps on getting USFDA`s final nod for Plerixafor Injection
Zydus Lifesciences rises on getting USFDA’s final nod for Oxcarbazepine Tablets Jul-05-2023 14:06 Hrs IST Zydus Lifesciences is currently trading at Rs. 582.10, up by 7.80 points or 1.36% from its previous closing of Rs. 574.30 on the BSE. The scrip opened at Rs. 574.85 and has touched a high and low of Rs. 583.25 and Rs. 573.90 respectively. So far 23649 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week ...
Zydus Lifesciences rises on getting USFDA`s final nod for Oxcarbazepine Tablets
Zydus Lifesciences is currently trading at Rs. 584.20, up by 2.15 points or 0.37% from its previous closing of Rs. 582.05 on the BSE. The scrip opened at Rs. 586.05 and has touched a high and low of Rs. 587.45 and Rs. 581.30 respectively. So far 4495 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 588.85 on 28-Jun-2023 and a 52 week low of Rs. 338.00 on 26-Jul-2022. Last one week high and low of the scrip stood ...
Zydus Lifesciences inches up on getting tentative nod from USFDA for Palbociclib Tablets
Zydus Lifesciences is currently trading at Rs. 559.20, up by 2.35 points or 0.42% from its previous closing of Rs. 556.85 on the BSE. The scrip opened at Rs. 560.00 and has touched a high and low of Rs. 563.50 and Rs. 558.10 respectively. So far 11529 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 564.50 on 21-Jun-2023 and a 52 week low of Rs. 338.00 on 26-Jul-2022. Last one week high and low of the scrip stood...
Zydus Lifesciences rises as its arm inks share purchase agreement to acquire stake in Mylab
Zydus Lifesciences is currently trading at Rs. 556.30, up by 1.95 points or 0.35% from its previous closing of Rs. 554.35 on the BSE. The scrip opened at Rs. 556.00 and has touched a high and low of Rs. 558.00 and Rs. 553.80 respectively. So far 16064 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 562.15 on 19-Jun-2023 and a 52 week low of Rs. 329.60 on 20-Jun-2022. Last one week high and low of the scrip stood...
Zydus Lifesciences gains on getting USFDA`s final nod for Minocycline Hydrochloride Extended-Release tablets
ZYDUS LIFE * We are seeing consistent buying in select pharma counters and Zyduslife is trading in sync. * Inching gradually higher for the last nine months, after the consolidation range breakout. * Witnessed a fresh breakout from a consolidation range. Holding strongly above 20 EMA. * We recommend creating fresh longs in the mentioned range. Buy Zydus Life Ltd CMP 549.15; Range 546-549; SL 532; Target 582 To Read Complete Report &...
Stock of the day: Buy Zydus Life Ltd For Target Rs.582 - Religare Broking
Zydus Lifesciences is currently trading at Rs. 520.35, up by 2.65 points or 0.51% from its previous closing of Rs. 517.70 on the BSE. The scrip opened at Rs. 522.60 and has touched a high and low of Rs. 523.15 and Rs. 515.85 respectively. So far 29575 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 530.70 on 09-May-2023 and a 52 week low of Rs. 329.60 on 20-Jun-2022. Last one week high and low of the scrip stood...
Zydus Lifesciences gains on getting USFDA`s final nod for Diclofenac Sodium and Misoprostol Delayed Release tablets
Zydus Lifesciences is currently trading at Rs. 518.60, up by 8.65 points or 1.70% from its previous closing of Rs. 509.95 on the BSE. The scrip opened at Rs. 510.05 and has touched a high and low of Rs. 519.10 and Rs. 508.80 respectively. So far 27356 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 530.70 on 09-May-2023 and a 52 week low of Rs. 329.60 on 20-Jun-2022. Last one week high and low of the scrip stood...
Zydus Lifesciences jumps on getting final approval from USFDA for Varenicline Tablets
ZYDUSLIF reported a stellar quarter with 30%YoY revenue growth and ~21% EBITDAM (exRevlimid) driven by US business increased contribution from gRevlimid and gTrokendi. Reported PAT was impacted by goodwill impairment pertaining to Sentynl Therapeutics’ legacy business. ZYDUSLIF’s 4Q US sales at USD 275mn improved QoQ and the near-term launch pipeline remains strong with 3 trans-dermal launches from Moraiya, 2-REMS products, gTrokendi ramp-up, gVascepa and gRevlimid. These launches...
Buy Zydus Lifesciences Ltd For Target Rs.570 - JM Financial Institutional Securities
Zydus Lifesciences is currently trading at Rs. 523.50, up by 3.60 points or 0.69 % from its previous closing of Rs. 519.90 on the BSE. The scrip opened at Rs. 523.50 and has touched a high and low of Rs. 523.50 and Rs. 523.50 respectively. So far 236 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 527.95 on 02-May-2023 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood ...
Zydus Lifesciences rises on getting final nod to manufacture, market Sucralfate Tablets
Zydus Lifesciences is currently trading at Rs. 522.75, up by 5.45 points or 1.05% from its previous closing of Rs. 517.30 on the BSE. The scrip opened at Rs. 517.30 and has touched a high and low of Rs. 524.35 and Rs. 516.00 respectively. So far 7326 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 524.35 on 24-Apr-2023 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood ...
Zydus Lifesciences rises on getting final nod for Icosapent Ethyl Capsules from USFDA
Zydus Lifesciences is currently trading at Rs. 517.10, up by 1.35 points or 0.26% from its previous closing of Rs. 515.75 on the BSE. The scrip opened at Rs. 519.70 and has touched a high and low of Rs. 519.70 and Rs. 514.50 respectively. So far 4781 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 519.70 on 19-Apr-2023 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip ...
Zydus Lifesciences inches up on getting USFDA`s final approval for Estradiol Transdermal System
Zydus Lifesciences is currently trading at Rs. 507.55, up by 3.90 points or 0.77% from its previous closing of Rs. 503.65 on the BSE. The scrip opened at Rs. 505.05 and has touched a high and low of Rs. 508.20 and Rs. 504.45 respectively. So far 2971 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 508.20 on 17-Apr-2023 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood ...
Zydus Lifesciences rises on getting USFDA`s final approval for Isoproterenol Hydrochloride Injection
Zydus Lifesciences is currently trading at Rs. 503.50, up by 2.70 points or 0.54% from its previous closing of Rs. 500.80 on the BSE. The scrip opened at Rs. 500.05 and has touched a high and low of Rs. 503.50 and Rs. 498.50 respectively. So far 15706 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 503.50 on 12-Apr-2023 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood...
Zydus Lifesciences hits 52 week high on getting USFDA`s final approval for Tavaborole Topical Solution
Zydus Lifesciences is currently trading at Rs. 497.65, up by 1.15 points or 0.23% from its previous closing of Rs. 496.50 on the BSE. The scrip opened at Rs. 499.65 and has touched a high and low of Rs. 501.35 and Rs. 493.60 respectively. So far 39687 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 501.35 on 11-Apr-2023 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood...
Zydus Lifesciences gains on getting USFDA`s final approval for Azithromycin Tablets
Indian pharma company Zydus Lifesciences has received final approval from the US Food and Drug Administration (FDA) to manufacture and market antibiotic Azithromycin used to treat bacterial infections, the company announced on Monday. "Zydus Lifesciences Limited (including its subsidiaries/affiliates) has received final approval from the US Food and Drug Administration (FDA) to manufacture and market Azithromycin tablets USP, 500 mg," the company said in a statement. Azithromy...
Zydus gets US FDA nod for antibiotic drug Azithromycin
Zydus Lifesciences is currently trading at Rs. 495.50, up by 2.30 points or 0.47% from its previous closing of Rs. 493.20 on the BSE. The scrip opened at Rs. 491.05 and has touched a high and low of Rs. 497.00 and Rs. 491.05 respectively. So far 19989 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 497.00 on 06-Apr-2023 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood a...
Zydus Lifesciences surges on getting USFDA`s final approval for Carbidopa and Levodopa Tablets
Zydus Lifesciences is currently trading at Rs 483.25, up by 0.95 points or 0.20% from its previous closing of Rs. 482.30 on the BSE. The scrip opened at Rs. 478.60 and has touched a high and low of Rs. 483.05 and Rs. 478.45 respectively. So far 10146 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 488.10 on 16-Mar-2023 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood ...
Zydus Lifesciences gains on getting USFDA`s final approval for Levothyroxine Sodium for Injection
NSE to roll back 6% transaction charges on equity and F&O trading from April 1: The board of National Stock Exchange (NSE) on March 24 stated that it has decided to rolled back the 6 percent increase in transaction charges on equity cash and derivatives segment, with effect from April 1.In January 2021, the charges were increased by 6 percent partly, to augment the investor corpus in view of certain market exigencies due to broker defaults. Zydus Recalls Over 55,000 Bottles Of Gener...
Key Stock Ideas: F&O, Zydus Lifesciences, TPG, - ARETE Securities
Zydus Lifesciences is currently trading at Rs. 483.15, up by 0.80 points or 0.17% from its previous closing of Rs. 482.35 on the BSE. The scrip opened at Rs. 480.35 and has touched a high and low of Rs. 483.40 and Rs. 478.65 respectively. So far 11881 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 488.10 on 16-Mar-2023 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood...
Zydus Lifesciences gains on getting USFDA`s final approval for Doxepin Hydrochloride Capsules
Zydus Lifesciences is currently trading at Rs. 483.20, up by 4.65 points or 0.97% from its previous closing of Rs. 478.55 on the BSE. The scrip opened at Rs. 478.60 and has touched a high and low of Rs. 484.50 and Rs. 478.20 respectively. So far 32866 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 488.10 on 16-Mar-2023 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood...
Zydus Lifesciences surges after its arm gets USFDA`s approval for Tofacitinib Tablets
Zydus Lifesciences is currently trading at Rs. 478.75, up by 2.90 points or 0.61% from its previous closing of Rs. 475.85 on the BSE. The scrip opened at Rs. 474.00 and has touched a high and low of Rs. 479.00 and Rs. 473.95 respectively. So far 7403 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 488.10 on 16-Mar-2023 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood ...
Zydus Lifesciences trades higher on getting orphan drug designation for ZYIL1 in treatment of patients with CAPS
Zydus Lifesciences is currently trading at Rs. 472.70, up by 3.75 points or 0.80% from its previous closing of Rs. 468.95 on the BSE. The scrip opened at Rs. 468.00 and has touched a high and low of Rs. 473.70 and Rs. 465.80 respectively. So far 22582 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 482.20 on 08-Feb-2023 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood...
Zydus Lifesciences rises on getting USFDA's final nod for Erythromycin Tablets
Zydus Lifesciences is currently trading at Rs. 477.80, up by 1.80 points or 0.38% from its previous closing of Rs. 476.00 on the BSE. The scrip opened at Rs. 474.05 and has touched a high and low of Rs. 478.25 and Rs. 473.05 respectively. So far 3309 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 482.20 on 08-Feb-2023 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood ...
Zydus Lifesciences inches up on getting USFDA`s final approval for Lenalidomide Capsules
Zydus Lifesciences is currently trading at Rs. 469.30, up by 3.75 points or 0.81% from its previous closing of Rs. 465.55 on the BSE. The scrip opened at Rs. 469.95 and has touched a high and low of Rs. 472.00 and Rs. 463.35 respectively. So far 6591 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 482.20 on 08-Feb-2023 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood ...
Zydus Lifesciences trades higher on getting USFDAs approval for Apixaban Tablets
Zydus Lifesciences is currently trading at Rs. 442.10, up by 0.85 points or 0.19% from its previous closing of Rs. 441.25 on the BSE. The scrip opened at Rs. 441.10 and has touched a high and low of Rs. 444.10 and Rs. 440.40 respectively. So far 4616 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 458.60 on 10-Jan-2023 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood ...
Zydus Lifesciences rises as its arm gets approval to market Levomilnacipran Extended-Release Capsules
Zydus Lifesciences is currently trading at Rs. 454.30, up by 2.15 points or 0.48% from its previous closing of Rs. 452.15 on the BSE. The scrip opened at Rs. 452.90 and has touched a high and low of Rs. 457.00 and Rs. 447.50 respectively. So far 17014 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 458.60 on 10-Jan-2023 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood...
Zydus Lifesciences rises as its arm gets USFDA`s final approval to market Brexpiprazole Tablets
Moraiya cleared; Revlimid launched Zydus Lifesciences (Zydus) reported Q2FY23 performance is broadly in line with our estimates. Revenue grew 7.3% YoY to Rs40.0bn (I-Sec: Rs40.0bn) on the back of India and US markets. US sales was up 5.9% QoQ to US$214mn led by new launches including Revlimid offsetting the base price erosion. Consumer business reported healthy growth of 12.0% YoY driven by demand for its key products. Adjusted EBITDA margin contracted 450bps YoY (+140bps QoQ) to 19.9%. Ad...
Hold Zydus Lifesciences Ltd For Target Rs. 448 - ICICI Securities
Zydus Lifesciences is currently trading at Rs. 423.85, up by 0.25 points or 0.06% from its previous closing of Rs. 423.60 on the BSE. The scrip opened at Rs. 423.60 and has touched a high and low of Rs. 425.30 and Rs. 419.55 respectively. So far 4111 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 487.00 on 03-Jan-2022 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood ...
Zydus Lifesciences inches up as its arm gets final approval from USFDA for Selexipag Tablets
Zydus Lifesciences is currently trading at Rs. 413.95, up by 2.65 points or 0.64% from its previous closing of Rs. 411.30 on the BSE. The scrip opened at Rs. 410.00 and has touched a high and low of Rs. 415.45 and Rs. 408.80 respectively. So far 43481 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 487.00 on 03-Jan-2022 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood...
Zydus Lifesciences surges on getting final approval from USFDA for Estradiol Transdermal System
India and US drives while Consumer Wellness and API drag earnings Product innovation a work-in-progress * ZYDUSLIF delivered a better-than-expected 2QFY23 performance, led by a superior product mix and controlled R&D spends. It continues to work on its innovation-led product pipeline as well as on complex generics to improve the growth in earnings going forward. * We reduced our FY23 earnings estimate by 3% to factor a moderation in profitability of Zydus Wellness, but increase o...
Netrual Zydus LifeSciences Ltd For Target Rs.410 - Motilal Oswal
Zydus Lifesciences is currently trading at Rs. 410.85, up by 1.40 points or 0.34% from its previous closing of Rs. 409.45 on the BSE. The scrip opened at Rs. 411.05 and has touched a high and low of Rs. 414.80 and Rs. 410.85 respectively. So far 3267 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 487.00 on 03-Jan-2022 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood ...
Zydus Lifesciences inches up on getting final approval to market Topiramate Extended-Release Capsules
Zydus Lifesciences is currently trading at Rs. 402.65, up by 0.85 points or 0.21% from its previous closing of Rs. 401.80 on the BSE. The scrip opened at Rs. 402.10 and has touched a high and low of Rs. 404.80 and Rs. 402.10 respectively. So far 1015 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 487.00 on 03-Jan-2022 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood ...
Zydus Lifesciences inches up as its arm receives USFDA`s approval for Levothyroxine Sodium for Injection
Zydus Lifesciences on Friday reported an 82.6% slump in second-quarter profit hit by rising expenses, sending its shares down 1.5%. Consolidated profit for the three months ended Sept. 30 was 5.23 billion Indian rupees ($64.69 million), compared with 30.02 billion rupees a year ago, the company said in an exchange filing. Analysts on average had expected a profit of 5.52 bln rupees, according to Refinitiv IBES data. The Ahmedabad-based company's total expenses climbed 15.3% to 35...
India's Zydus Lifesciences Q2 profit plunges on rising costs
Zydus Lifesciences is currently trading at Rs. 444.15, up by 4.35 points or 0.99% from its previous closing of Rs. 439.80 on the BSE. The scrip opened at Rs. 445.00 and has touched a high and low of Rs. 447.95 and Rs. 443.15 respectively. So far 6559 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 510.00 on 09-Nov-2021 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood ...
Zydus Lifesciences gains on getting EIR for formulations manufacturing facility in Moraiya from USFDA
Zydus Lifesciences is currently trading at Rs. 437.25, up by 7.75 points or 1.80% from its previous closing of Rs. 429.50 on the BSE. The scrip opened at Rs. 430.00 and has touched a high and low of Rs. 439.85 and Rs. 430.00 respectively. So far 689 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 511.90 on 29-Oct-2021 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood a...
Zydus Lifesciences shines on getting final approval from USFDA for Acetaminophen injection
Zydus Lifesciences is currently trading at Rs. 413.20, up by 0.05 points or 0.01% from its previous closing of Rs. 413.15 on the BSE. The scrip opened at Rs. 414.50 and has touched a high and low of Rs. 415.00 and Rs. 411.65 respectively. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 514.70 on 27-Oct-2021 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood at Rs. 419.30 and Rs. 408.55 respectively. The ...
Zydus Lifesciences inches up on getting final approval from USFDA for Ketorolac Tromethamine Tablets
BUY ARVIND FASHIONS LTD Scrip : ARVINDFASN; Sentiment: BULLISH; Entry : 310-290; Stop Loss: 230; Target :1 400; Target 2 : 440 *In the calendar year of 2021; ARVINDFASN rallied more than 150% in a matter of just 3 months (From 135 it went above 360 mark). Then after it corrected 61.8% of the entire move and has been consolidating. *At this juncture; it is again on the verge of fresh breakout and that indicates a continuation of the pr...
Diwali 2022 : Technical picks By Anand Rathi Share and Stock Brokers
Zydus Lifesciences is currently trading at Rs. 416.30, up by 4.90 points or 1.19% from its previous closing of Rs. 411.40 on the BSE. The scrip opened at Rs. 411.05 and has touched a high and low of Rs. 416.90 and Rs. 409.00 respectively. So far 9982 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 545.00 on 18-Oct-2021 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood ...
Zydus Lifesciences jumps after its arm receives tentative approval from USFDA for Roflumilast Tablets
Zydus Lifesciences is currently trading at Rs. 423.00, up by 3.00 points or 0.71% from its previous closing of Rs. 420.00 on the BSE. The scrip opened at Rs. 419.15 and has touched a high and low of Rs. 424.30 and Rs. 419.15 respectively. So far 36044 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 566.65 on 05-Oct-2021 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood...
Zydus Lifesciences gains on getting final nod from USFDA for Brivaracetam Tablets
Maruti Suzuki India vehicle production rises two-fold to 177k units in Sep Maruti Suzuki India on Monday reported an over two-fold rise in its vehicle production at 1,77,468 units in September 2022. The company had produced a total of 81,278 units in the same month last year. "The shortage of electronic components had a minor impact on the production of vehicles during the month," Maruti Suzuki India said in a regulatory filing. JSW Cement secures Rs 400 cr as sustainability-l...
Key Stock News: Maruti Suzuki, JSW Cement, fintech, Nykaa, Zee Entertainment, Zydus Lifesciences - ARETE Securities
Zydus Lifesciences is currently trading at Rs. 394.50, up by 7.80 points or 2.02% from its previous closing of Rs. 386.70 on the BSE. The scrip opened at Rs. 386.05 and has touched a high and low of Rs. 394.65 and Rs. 386.05 respectively. So far 15053 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 572.90 on 04-Oct-2021 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood...
Zydus Lifesciences surges as its arm gets nod to market Mirabegron Extended-Release Tablets
Zydus Lifesciences is currently trading at Rs. 371.00, up by 11.30 points or 3.14% from its previous closing of Rs. 359.70 on the BSE. The scrip opened at Rs. 359.35 and has touched a high and low of Rs. 370.40 and Rs. 359.35 respectively. So far 23797 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 572.90 on 04-Oct-2021 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stoo...
Zydus Lifesciences moves up on launching Lenalidomide Capsules in US
Zydus Lifesciences is currently trading at Rs. 376.90, up by 0.35 points or 0.09% from its previous closing of Rs. 376.55 on the BSE. The scrip opened at Rs. 376.65 and has touched a high and low of Rs. 379.25 and Rs. 374.40 respectively. So far 21775 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 572.90 on 04-Oct-2021 and a 52 week low of Rs. 319.40 on 11-May-2022. Last one week high and low of the scrip stood...
Zydus Lifesciences gains on getting gets final approval from USFDA for Lenalidomide Capsules
Load More